胰高血糖素样肽-1受体激动剂与甲状腺癌:一篇叙述性综述
本叙述性综述汇总基础与转化研究、随机试验、观察性研究和药物警戒研究,评估胰高血糖素样肽-1受体激动剂(GLP-1 RA)与甲状腺癌的关联。随机对照试验证据显示甲状腺癌事件罕见,效应估计不精确,无 conclusive 风险升高证据;观察性研究结果不一致;药物警戒研究持续显示报告信号。
要点
- 随机试验及其Meta分析提示GLP-1 RA使用者甲状腺癌罕见,效应估计不精确,无一致风险升高证据。
- 观察性研究偏倚风险较高,甲状腺癌事件率低,不同研究间效应估计不一致。
- 药物警戒研究一致显示GLP-1 RA治疗患者甲状腺癌报告增加信号,但不解决因果性。
核心结论
- 随机对照试验证据表明暴露于GLP-1 RA的个体中甲状腺癌发生不频繁,观察性研究偏倚风险较高且结果不一致,总体无甲状腺癌风险升高的 conclusive 证据。
研究设计与样本
- 叙述性综述,证据涵盖基础与转化研究、随机试验、观察性研究和药物警戒研究。
主要发现
- 啮齿类动物中有生物学合理性支持GLP-1 RA与甲状腺髓样癌(MTC)的关联,在人类中对非MTC的关联较不明确。
- 随机试验及相关Meta分析提示甲状腺癌为罕见事件,效应估计不精确,无 conclusive 且一致的证据表明接受GLP-1 RA者风险增加。
- 偏倚风险较高的观察性研究也显示甲状腺癌事件率低,不同研究间效应估计不一致。
- 药物警戒研究一致显示接受GLP-1 RA治疗的患者中甲状腺癌报告增加信号。
临床怎么用
- 这些发现可帮助临床医生处理患者对GLP-1 RA治疗与甲状腺癌之间潜在但未经证实的关联的担忧。
局限性
- 观察性研究对协变量评估有限或结局定义不可靠。
- 药物警戒研究提供上市后安全性信号评估但不解决因果性。
- 随机试验中甲状腺癌为罕见事件使效应估计不精确。
- 观察性研究偏倚风险较高且不同研究间效应估计不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective medications for the treatment of type 2 diabetes and obesity. Pharmacological studies in rodents support an association between the use of GLP-1 RAs and the development of medullary thyroid cancer (MTC) resulting in a black box warning for these agents in patients at risk for this condition. Yet, the association between GLP-1 RAs and non-MTC remains controversial. Excessive worry about unproven thyroid cancer risk might lead to underutilizing GLP-1 RAs in patients who could otherwise experience substantial benefits. Unwarranted concerns about thyroid cancer could lead to unnecessary thyroid cancer screening and harms from overdiagnosis. Summary: The body of evidence assessing the association between GLP-1 RA use and thyroid cancer spans a wide range of methodologies, including basic and translational research investigating biological plausibility; randomized trials assessing clinical efficacy and providing the strongest evidence for causality; observational studies providing real-life outcome evaluation in larger populations but with limited evaluation of covariates or dependable outcome definitions; and pharmacovigilance studies that provide postmarketing assessments of a safety signal but do not address causality. There is biological plausibility supporting an association between GLP-1 RA and MTC in rodents, which is less clear for non-MTC in humans. Clinical evidence from randomized trials and associated meta-analysis suggest thyroid cancer as a rare event making effect estimates imprecise but without conclusive and consistent evidence of increase risk in those receiving GLP-1 RA. Observational studies at higher risk of bias also show low event rates for thyroid cancer, with effect estimates that are inconsistent among different studies. Pharmacovigilance studies consistently show a signal of increased reporting of thyroid cancer in patients treated with GLP-1 RA. Conclusions: Evidence from randomized controlled trials indicates occurrence of thyroid cancer is infrequent in individuals exposed to GLP-1 RA. Observational studies at higher risk of bias yield inconsistent results. Overall there is no conclusive evidence of elevated thyroid cancer risk. These findings can help clinicians when addressing patient's concerns about a potential yet unproven link between GLP-1 RA therapy and thyroid cancer.
引用
- Espinosa De Ycaza AE, Brito JP, McCoy RG, et al. Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review. Thyroid. 2024. PMID: 38343381. doi:10.1089/thy.2023.0530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。